Merida Biosciences develops novel precision therapies targeting the pathogenic drivers of antibody-driven autoimmune diseases. Their platform aims to eliminate disease roots with high specificity, offering durable clinical responses where current non-specific treatments fall short. The company focuses on the discovery and development of highly specific immunotherapies for patients suffering from autoimmune and allergic disorders.
Funding
$121M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCBVFounders
Product
Problem
Current therapies for autoimmune and allergic diseases rely on broad immunosuppression, which often yields limited efficacy and carries a high risk of adverse effects. Clinicians lack agents that can selectively neutralize the pathogenic antibodies driving disease pathology, leading to suboptimal disease control and frequent relapses. Consequently, patients experience persistent symptoms and reduced quality of life.
Solution
Merida Biosciences has built a precision immunology platform that identifies and validates the specific antibody-driven mechanisms underlying each autoimmune condition. Using advanced antibody engineering, the platform generates highly selective therapeutic candidates—such as bispecific antibodies and Fc-fusion constructs—that bind and eliminate the disease‑causing antibodies while sparing normal immune function. Integrated target‑discovery pipelines, high‑throughput screening, and structure‑guided design accelerate candidate selection. The resulting molecules are optimized for durability, manufacturability, and favorable pharmacokinetics through a dedicated CMC workflow. Preclinical and early clinical programs focus on delivering durable clinical responses with a safety profile superior to conventional immunosuppressants.
Target Audience
The primary customers are pharmaceutical and biotech companies seeking to develop next‑generation, mechanism‑based therapies for antibody‑mediated autoimmune and allergic disorders, as well as clinicians treating patients with refractory disease who require more precise therapeutic options.
Features
- Target‑centric discovery engine that maps pathogenic autoantibody repertoires and selects disease‑specific epitopes.
- Proprietary antibody‑engineering platform enabling bispecific and Fc‑engineered formats with picomolar affinity and selective FcγR engagement.
- Adaptive preclinical pipeline that combines in‑vitro functional assays, humanized mouse models, and biomarker‑driven readouts to de‑risk candidate progression.
- End‑to‑end CMC suite covering cell‑line development, scalable bioprocessing, and GMP‑compliant manufacturing for rapid IND filing.
- Integrated safety assessment framework leveraging immunogenicity prediction, off‑target profiling, and longitudinal PK/PD modeling.
- Cloud‑based data analytics platform that consolidates omics, clinical, and manufacturing data to inform iterative design cycles.
- Modular partnership model that allows co‑development or licensing of platform‑derived candidates to pharmaceutical collaborators.